Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target ...
The American Journal of Managed Care2h
Lesion Repair, Damage Processes Correlate With MS Disease Characteristics
New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple ...
Too Old to Operate6h
Decision-Making, Emotional Impact, and Adjustment in Patients with MS Undergoing HSCT
The following is a summary of “A qualitative study on the experiences of autologous haematopoietic stem cell transplant for Multiple Sclerosis,” published in the November 2024 issue of Neurology by ...
Too Old to Operate6h
Economic Evaluations of MS Treatments Across Global Cost-Effectiveness Studies
The following is a summary of “Untackling the economics of Multiple Sclerosis: a systematic review of economic evaluations of disease-modifying therapies indicated for Multiple Sclerosis,” published ...
Romper6h
My Son's Bar Mitzvah Has Me Wishing For Just One Day Without MS
I opened the calendar on my phone and confirmed that there were 38 days until my son’s bar mitzvah. If only I could have one day, I thought — a day in a normal body. My son’s bar mitzvah is a symbolic ...
charitytoday.co.uk12h
MS Trust and MS Research Unite to Strengthen Support for MS Community
This strategic collaboration will enable the charities to build on the services they already offer the MS Community. By ...
Managed Healthcare Executive19h
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Multiple sclerosis (MS) is characterized by chronic inflammation leading to ... and less disease activity but show more evidence of neuronal degeneration. Current treatment guidelines recommend ...